Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT05436418
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸City of Hope, Duarte, California, United States
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 225
- Registration Number
- NCT05382338
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05115630
- Locations
- 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT04959175
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Interventions
- Drug: BusulfanRadiation: Total-body irradiationDrug: MelphalanDrug: CyclophosphamideDrug: FludarabineProcedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)Procedure: Bone Marrow Hematopoietic Stem Cell TransplantationDrug: Post-transplant CyclophosphamideDrug: MesnaDrug: TacrolimusDrug: Mycophenolate MofetilOther: Patient-Reported Outcomes
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 300
- Registration Number
- NCT04904588
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- Conditions
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04897321
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.